98%
921
2 minutes
20
Purpose: People with COPD are at a higher risk of cognitive dysfunction than the general population. However, the additional impact of dementia amongst such patients is not well understood, particularly in those admitted with a COPD exacerbation. We assessed the impact of coexisting dementia on inpatient mortality and length of stay (LOS) in patients admitted to hospital with a COPD exacerbation, using the United States based National Inpatient Sample database.
Patients And Methods: Patients aged over 40 years and hospitalised with a primary diagnosis of COPD exacerbation from 2011 to 2015 were included. Cases were grouped into patients with and without dementia. Multivariable logistic regression analysis, stratified by age, was used to assess risk of inpatient deaths. Cox regression was carried out to compare death rates and competing risk analysis gave estimates of discharge rates with time to death a competing variable.
Results: A total of 576,381 patients were included into the analysis, of which 35,372 (6.1%) had co-existent dementia. There were 6413 (1.1%) deaths recorded. The odds of inpatient death were significantly greater in younger patients with dementia (41-64 years) [OR (95% CI) dementia vs without: 1.75 (1.04-2.92), p=0.03]. Cases with dementia also had a higher inpatient mortality rate in the first 4 days [HR (95% CI) dementia vs without: 1.23 (1.08-1.41), p=0.002] and a longer LOS [sub-hazard ratio (95% CI) dementia vs without: 0.93 (0.92-0.94), p<0.001].
Conclusion: Dementia as a comorbidity is associated with worse outcomes based on inpatient deaths and LOS in patients admitted with COPD exacerbations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921839 | PMC |
http://dx.doi.org/10.2147/COPD.S345751 | DOI Listing |
Introduction Chronic Obstructive Pulmonary Disease (COPD) is increasingly recognized not only as a pulmonary condition but as a systemic disorder with significant cardiovascular implications. Acute exacerbations of COPD (AECOPD) further elevate this risk, potentially through a heightened prothrombotic state. This study aimed to evaluate and compare the levels of select prothrombotic biomarkers - fibrinogen, C-reactive protein (CRP), D-dimer, von Willebrand Factor (vWF), homocysteine, lactate dehydrogenase (LDH), and platelet-to-lymphocyte ratio (PLR) - in patients with stable COPD and AECOPD, and to assess their diagnostic and prognostic significance.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Dipeptidyl peptidase 1 (DPP1) inhibitors constitute a major advance in respiratory disease therapeutics. Through selective blockade of neutrophil serine protease (NSP) activation, these agents establish novel treatment paradigms for inflammatory respiratory conditions characterized by neutrophil-driven pathology. This comprehensive review examines the development status, clinical efficacy, and safety profile of DPP1 inhibitors in neutrophil-driven diseases, particularly non-cystic fibrosis bronchiectasis (NCFBE) and chronic obstructive pulmonary disease (COPD).
View Article and Find Full Text PDFInt J Chron Obstruct Pulmon Dis
September 2025
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.
Background: Chronic obstructive pulmonary disease (COPD) is a major health concern in Korea, with a higher burden of acute exacerbations (AE-COPD) compared to Western populations. Environmental exposures such as smoking and air pollution are known contributors, but the impact of urban green space remains underexplored.
Methods: We conducted a cohort study using the Korean National Health Insurance Service-National Sample Cohort (2006-2019), including 5,171 patients aged ≥40 years with at least two COPD-related prescriptions within one year.
Can Respir J
September 2025
Department of Pulmonology, Sutcu Imam University Faculty of Medicine, Kahramanmaras, Turkey.
Chronic obstructive pulmonary disease (COPD) is an increasing cause of morbidity and mortality worldwide, and acute exacerbations are the major health issues in COPD patients. In this study, we aimed to investigate the role of the delta neutrophil index (DNI) with other hematologic parameters in managing and guiding COPD patients admitted with acute exacerbations. In this retrospective study, COPD patients treated internally in pulmonology clinic, intensive care unit, and anesthesiology and reanimation unit with acute exacerbation between May 2021 and December 2023 were investigated.
View Article and Find Full Text PDFRespir Med
September 2025
Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom. Electronic address:
Background: Eosinophilic chronic obstructive pulmonary disease (eCOPD), characterized by type 2 inflammation, is an emerging target for biologic therapies.
Objective: To indirectly compare the efficacy of dupilumab and mepolizumab in eCOPD, defined as blood eosinophil counts ≥300 cells/μL, by synthesizing data from phase 3 randomized controlled trials: BOREAS and NOTUS for dupilumab, MATINEE for mepolizumab.
Methods: We performed an indirect comparison of trial primary and secondary outcomes including annual exacerbation rates (AER), quality of life (St.